Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Identifieur interne : 000B62 ( Main/Exploration ); précédent : 000B61; suivant : 000B63Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Auteurs : Clement A. Meseda [États-Unis] ; Vajini Atukorale [États-Unis] ; Jordan Kuhn [États-Unis] ; Falko Schmeisser [États-Unis] ; Jerry P. Weir [États-Unis]Source :
- PloS one [ 1932-6203 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps neutralisants (immunologie), Cytokines (métabolisme), Herpèsvirus humain de type 2 (immunologie), Immunoglobuline G (immunologie), Modèles animaux de maladie humaine, Souris, Sous-type H5N1 du virus de la grippe A (immunologie), Vaccination, Vaccine (), Vaccine (métabolisme), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (génétique), Vaccins contre les virus herpès simplex (administration et posologie), Vecteurs génétiques (administration et posologie), Vecteurs génétiques (génétique), Virus de la vaccine (génétique), Virus de la vaccine (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux, Vaccins contre les virus herpès simplex, Vecteurs génétiques.
- génétique : Vaccins antiviraux, Vecteurs génétiques, Virus de la vaccine.
- immunologie : Anticorps antiviraux, Anticorps neutralisants, Herpèsvirus humain de type 2, Immunoglobuline G, Sous-type H5N1 du virus de la grippe A, Virus de la vaccine.
- métabolisme : Cytokines, Vaccine.
- Animaux, Modèles animaux de maladie humaine, Souris, Vaccination, Vaccine.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (immunology), Antibodies, Viral (immunology), Cytokines (metabolism), Disease Models, Animal, Genetic Vectors (administration & dosage), Genetic Vectors (genetics), Herpes Simplex Virus Vaccines (administration & dosage), Herpesvirus 2, Human (immunology), Immunoglobulin G (immunology), Influenza A Virus, H5N1 Subtype (immunology), Mice, Vaccination, Vaccinia (metabolism), Vaccinia (prevention & control), Vaccinia virus (genetics), Vaccinia virus (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics).
- MESH :
- chemical , administration & dosage : Herpes Simplex Virus Vaccines, Viral Vaccines.
- chemical , genetics : Viral Vaccines.
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, Immunoglobulin G.
- chemical , metabolism : Cytokines.
- administration & dosage : Genetic Vectors.
- genetics : Genetic Vectors, Vaccinia virus.
- immunology : Herpesvirus 2, Human, Influenza A Virus, H5N1 Subtype, Vaccinia virus.
- metabolism : Vaccinia.
- prevention & control : Vaccinia.
- Animals, Disease Models, Animal, Mice, Vaccination.
Abstract
The robustness of immune responses to an antigen could be dictated by the route of vaccine inoculation. Traditional smallpox vaccines, essentially vaccinia virus strains, that were used in the eradication of smallpox were administered by percutaneous inoculation (skin scarification). The modified vaccinia virus Ankara is licensed as a smallpox vaccine in Europe and Canada and currently undergoing clinical development in the United States. MVA is also being investigated as a vector for the delivery of heterologous genes for prophylactic or therapeutic immunization. Since MVA is replication-deficient, MVA and MVA-vectored vaccines are often inoculated through the intramuscular, intradermal or subcutaneous routes. Vaccine inoculation via the intramuscular, intradermal or subcutaneous routes requires the use of injection needles, and an estimated 10 to 20% of the population of the United States has needle phobia. Following an observation in our laboratory that a replication-deficient recombinant vaccinia virus derived from the New York City Board of Health strain elicited protective immune responses in a mouse model upon inoculation by tail scarification, we investigated whether MVA and MVA recombinants can elicit protective responses following percutaneous administration in mouse models. Our data suggest that MVA administered by percutaneous inoculation, elicited vaccinia-specific antibody responses, and protected mice from lethal vaccinia virus challenge, at levels comparable to or better than subcutaneous or intramuscular inoculation. High titers of specific neutralizing antibodies were elicited in mice inoculated with a recombinant MVA expressing the herpes simplex type 2 glycoprotein D after scarification. Similarly, a recombinant MVA expressing the hemagglutinin of attenuated influenza virus rgA/Viet Nam/1203/2004 (H5N1) elicited protective immune responses when administered at low doses by scarification. Taken together, our data suggest that MVA and MVA-vectored vaccines inoculated by scarification can elicit protective immune responses that are comparable to subcutaneous vaccination, and may allow for antigen sparing when vaccine supply is limited.
DOI: 10.1371/journal.pone.0149364
PubMed: 26895072
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000372
- to stream PubMed, to step Curation: 000371
- to stream PubMed, to step Checkpoint: 000353
- to stream Ncbi, to step Merge: 000781
- to stream Ncbi, to step Curation: 000781
- to stream Ncbi, to step Checkpoint: 000781
- to stream Main, to step Merge: 000B62
- to stream Main, to step Curation: 000B62
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.</title>
<author><name sortKey="Meseda, Clement A" sort="Meseda, Clement A" uniqKey="Meseda C" first="Clement A" last="Meseda">Clement A. Meseda</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Atukorale, Vajini" sort="Atukorale, Vajini" uniqKey="Atukorale V" first="Vajini" last="Atukorale">Vajini Atukorale</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuhn, Jordan" sort="Kuhn, Jordan" uniqKey="Kuhn J" first="Jordan" last="Kuhn">Jordan Kuhn</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schmeisser, Falko" sort="Schmeisser, Falko" uniqKey="Schmeisser F" first="Falko" last="Schmeisser">Falko Schmeisser</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weir, Jerry P" sort="Weir, Jerry P" uniqKey="Weir J" first="Jerry P" last="Weir">Jerry P. Weir</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26895072</idno>
<idno type="pmid">26895072</idno>
<idno type="doi">10.1371/journal.pone.0149364</idno>
<idno type="wicri:Area/PubMed/Corpus">000372</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000372</idno>
<idno type="wicri:Area/PubMed/Curation">000371</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000371</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000353</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000353</idno>
<idno type="wicri:Area/Ncbi/Merge">000781</idno>
<idno type="wicri:Area/Ncbi/Curation">000781</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000781</idno>
<idno type="wicri:Area/Main/Merge">000B62</idno>
<idno type="wicri:Area/Main/Curation">000B62</idno>
<idno type="wicri:Area/Main/Exploration">000B62</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.</title>
<author><name sortKey="Meseda, Clement A" sort="Meseda, Clement A" uniqKey="Meseda C" first="Clement A" last="Meseda">Clement A. Meseda</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Atukorale, Vajini" sort="Atukorale, Vajini" uniqKey="Atukorale V" first="Vajini" last="Atukorale">Vajini Atukorale</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuhn, Jordan" sort="Kuhn, Jordan" uniqKey="Kuhn J" first="Jordan" last="Kuhn">Jordan Kuhn</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schmeisser, Falko" sort="Schmeisser, Falko" uniqKey="Schmeisser F" first="Falko" last="Schmeisser">Falko Schmeisser</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weir, Jerry P" sort="Weir, Jerry P" uniqKey="Weir J" first="Jerry P" last="Weir">Jerry P. Weir</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993</wicri:regionArea>
<wicri:noRegion>20993</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Cytokines (metabolism)</term>
<term>Disease Models, Animal</term>
<term>Genetic Vectors (administration & dosage)</term>
<term>Genetic Vectors (genetics)</term>
<term>Herpes Simplex Virus Vaccines (administration & dosage)</term>
<term>Herpesvirus 2, Human (immunology)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Mice</term>
<term>Vaccination</term>
<term>Vaccinia (metabolism)</term>
<term>Vaccinia (prevention & control)</term>
<term>Vaccinia virus (genetics)</term>
<term>Vaccinia virus (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Cytokines (métabolisme)</term>
<term>Herpèsvirus humain de type 2 (immunologie)</term>
<term>Immunoglobuline G (immunologie)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Souris</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Vaccination</term>
<term>Vaccine ()</term>
<term>Vaccine (métabolisme)</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins contre les virus herpès simplex (administration et posologie)</term>
<term>Vecteurs génétiques (administration et posologie)</term>
<term>Vecteurs génétiques (génétique)</term>
<term>Virus de la vaccine (génétique)</term>
<term>Virus de la vaccine (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Herpes Simplex Virus Vaccines</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Genetic Vectors</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vaccins contre les virus herpès simplex</term>
<term>Vecteurs génétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Genetic Vectors</term>
<term>Vaccinia virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vecteurs génétiques</term>
<term>Virus de la vaccine</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
<term>Herpèsvirus humain de type 2</term>
<term>Immunoglobuline G</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Virus de la vaccine</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Herpesvirus 2, Human</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>Vaccinia virus</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Vaccinia</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Vaccinia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Mice</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Modèles animaux de maladie humaine</term>
<term>Souris</term>
<term>Vaccination</term>
<term>Vaccine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The robustness of immune responses to an antigen could be dictated by the route of vaccine inoculation. Traditional smallpox vaccines, essentially vaccinia virus strains, that were used in the eradication of smallpox were administered by percutaneous inoculation (skin scarification). The modified vaccinia virus Ankara is licensed as a smallpox vaccine in Europe and Canada and currently undergoing clinical development in the United States. MVA is also being investigated as a vector for the delivery of heterologous genes for prophylactic or therapeutic immunization. Since MVA is replication-deficient, MVA and MVA-vectored vaccines are often inoculated through the intramuscular, intradermal or subcutaneous routes. Vaccine inoculation via the intramuscular, intradermal or subcutaneous routes requires the use of injection needles, and an estimated 10 to 20% of the population of the United States has needle phobia. Following an observation in our laboratory that a replication-deficient recombinant vaccinia virus derived from the New York City Board of Health strain elicited protective immune responses in a mouse model upon inoculation by tail scarification, we investigated whether MVA and MVA recombinants can elicit protective responses following percutaneous administration in mouse models. Our data suggest that MVA administered by percutaneous inoculation, elicited vaccinia-specific antibody responses, and protected mice from lethal vaccinia virus challenge, at levels comparable to or better than subcutaneous or intramuscular inoculation. High titers of specific neutralizing antibodies were elicited in mice inoculated with a recombinant MVA expressing the herpes simplex type 2 glycoprotein D after scarification. Similarly, a recombinant MVA expressing the hemagglutinin of attenuated influenza virus rgA/Viet Nam/1203/2004 (H5N1) elicited protective immune responses when administered at low doses by scarification. Taken together, our data suggest that MVA and MVA-vectored vaccines inoculated by scarification can elicit protective immune responses that are comparable to subcutaneous vaccination, and may allow for antigen sparing when vaccine supply is limited. </div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Meseda, Clement A" sort="Meseda, Clement A" uniqKey="Meseda C" first="Clement A" last="Meseda">Clement A. Meseda</name>
</noRegion>
<name sortKey="Atukorale, Vajini" sort="Atukorale, Vajini" uniqKey="Atukorale V" first="Vajini" last="Atukorale">Vajini Atukorale</name>
<name sortKey="Kuhn, Jordan" sort="Kuhn, Jordan" uniqKey="Kuhn J" first="Jordan" last="Kuhn">Jordan Kuhn</name>
<name sortKey="Schmeisser, Falko" sort="Schmeisser, Falko" uniqKey="Schmeisser F" first="Falko" last="Schmeisser">Falko Schmeisser</name>
<name sortKey="Weir, Jerry P" sort="Weir, Jerry P" uniqKey="Weir J" first="Jerry P" last="Weir">Jerry P. Weir</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B62 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B62 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= StressCovidV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:26895072 |texte= Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26895072" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a StressCovidV1
This area was generated with Dilib version V0.6.33. |